Table 1.
Clinical Parameters and Biomarker Levels†
| All (n = 299) | Men (n = 95) | Women (n = 204) | p-value | |
|---|---|---|---|---|
| Clinical parameter, mean (range) | ||||
| Age, years | 63.0 (37–92) | 62.7 (38–92) | 63.3 (37–89) | 0.707 |
| Systolic BP (mm Hg) | 132.3 (91–210) | 131.7 (92–180) | 132.6 (91–210) | 0.860 |
| Diastolic BP (mm Hg) | 76.0 (44–120) | 76.2 (44–100) | 76.0 (50–120) | 0.852 |
| Body mass index, kg/m2 | 25.9 (15.7–49.5) | 25.9 (15.7–49.5) | 26.0 (17.4–42.3) | 0.842 |
| Statin dosage | ||||
| Low intensity | 176 (58.9) | 50 (52.6) | 126 (61.8) | 0.306 |
| Moderate intensity | 116 (38.8) | 42 (44.2) | 74 (36.3) | |
| High intensity | 7 (2.3) | 3 (3.2) | 4 (2.0) | |
| CETP Polymorphisms | ||||
| rs3764261 (C>A) genotype | ||||
| CC | 126 (42.1) | 40 (42.1) | 86 (42.2) | 0.822 |
| CA | 140 (46.8) | 43 (45.3) | 97 (47.5) | |
| AA | 33 (11.0) | 12 (12.6) | 21 (10.3) | |
| rs708272 (G>A) genotype | ||||
| GG | 101 (33.8) | 34 (35.8) | 67 (32.8) | 0.760 |
| GA | 153 (51.2) | 49 (51.6) | 104 (51.0) | |
| AA | 45 (15.0) | 12 (12.6) | 33 (16.2) | |
| rs12149545 (G>A) genotype | ||||
| GG | 193 (64.5) | 61 (64.2) | 132 (64.7) | 0.993 |
| GA | 97 (32.5) | 31 (32.6) | 66 (32.4) | |
| AA | 9 (3.0) | 3 (3.2) | 6 (2.9) | |
| Biomarkers | ||||
| Fasting glucose, mmol/L | 5.78 (5.17–7.15) | 6.44 (5.33–8.14) | 5.67 (5.12–6.82) | 0.001 |
| Insulin, μIU/mL | 7.0 (4.8–10.7) | 7.3 (4.8–10.8) | 7.0 (4.7–10.7) | 0.965 |
| HOMA-IR | 1.98 (1.19–3.17) | 2.05 (1.37–3.72) | 1.90 (1.14–3.04) | 0.157 |
| HbA1c (mmol/mol) | 47.7 (41.2–58.7) | 51.1 (41.6–62.1) | 46.7 (40.1–56.5) | 0.039 |
Notes: †Continuous data are given as median (interquartile range). Categorical variables are presented as numbers (%). All biochemical measures are given in Système International units; conversions to conventional units are as follows: fasting glucose (mg/dL), multiply by 18.02; HbA1c (%), use the formula: [0.0915 HbA1c (mmol/mol) + 2.15].
Abbreviations: BP, blood pressure; HOMAIR, homeostasis model assessment of insulin resistance.